Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous
system and can result in disability. Although the prevalence of MS has increased in India …

Background Multiple sclerosis typically has onset in young adults and new disease activity
diminishes with age. Most clinical trials of disease-modifying therapies for multiple sclerosis …

With a rapidly aging global population and improvement of outcomes with newer multiple
sclerosis (MS)-specific disease-modifying therapies (DMTs), the epidemiology of MS has …

Background and purpose There is a lack of evidence guiding discontinuation of disease‐
modifying therapy (DMT) in relapsing multiple sclerosis (RMS). Thus, the objective of this …

Background Multiple sclerosis (MS) patients with stable disease course might view
continued treatment as unnecessary. However, guidelines regarding treatment …

Stopping disease-modifying therapy in relapsing and progress... : Current Opinion in Neurology
Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis : Current …

Abstract Purpose of Review Long-term use of multiple sclerosis (MS) disease-modifying
therapies (DMTs) is standard practice to prevent accumulation of disability …

Introduction: The successful development of anti-inflammatory disease-modifying treatments
(DMT) significantly improved disease outcomes and longevity of persons with multiple …

Conclusions Developing effective disease modifying therapies that slow or stop the gradual
accumulation of neurologic disability in progressive MS represents a critical unmet need. As …

Background Patients with relapsing multiple sclerosis (RMS) are maintained on disease-
modifying therapy (DMT) to prevent disease progression. Reported persistence rates to …